Hayes Don, Galantowicz Mark, Yates Andrew R, Preston Thomas J, Mansour Heidi M, McConnell Patrick I
Department of Pediatrics, The Ohio State University College of Medicine, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA,
J Artif Organs. 2013 Sep;16(3):382-5. doi: 10.1007/s10047-013-0699-z. Epub 2013 Mar 19.
Extracorporeal membrane oxygenation (ECMO) is an established therapy for primary graft dysfunction (PGD) in adults after lung transplant, while venovenous (VV) ECMO is an evolving therapy that can bridge patients to lung transplantation. This report describes a case of relatively quick improvement of grade 3 PGD, based on the PaO2/FIO2 (P/F) ratio, in a 17-year-old patient with cystic fibrosis who was bridged to lung transplantation with ambulatory VV ECMO and then received support with VV ECMO as a protective strategy during the initial phases of PGD after lung transplantation.
体外膜肺氧合(ECMO)是成人肺移植后原发性移植肺功能障碍(PGD)的一种既定治疗方法,而静脉-静脉(VV)ECMO是一种不断发展的治疗方法,可作为患者肺移植的过渡治疗手段。本报告描述了一例17岁囊性纤维化患者,其基于动脉血氧分压/吸入氧分数值(PaO2/FIO2,P/F)比值的3级PGD得到了相对快速的改善。该患者通过门诊VV ECMO过渡到肺移植,然后在肺移植后PGD的初始阶段接受VV ECMO支持作为一种保护策略。